CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.

CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane associated molecules in different cells and tissues hav...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alain Geloen, Lionel Helin, Benjamine Geeraert, Eric Malaud, Paul Holvoet, Gerard Marguerie
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4639332cd7ca4104a34711ed04f4f491
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4639332cd7ca4104a34711ed04f4f491
record_format	dspace
spelling	oai:doaj.org-article:4639332cd7ca4104a34711ed04f4f4912021-11-18T07:17:22ZCD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.1932-620310.1371/journal.pone.0037633https://doaj.org/article/4639332cd7ca4104a34711ed04f4f4912012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22662181/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane associated molecules in different cells and tissues have however questioned its potential as a therapeutic target. The present study shows that it is possible to identify low molecular weight chemicals that can block the CD36 binding and uptake functions. These inhibitors were able to reduce arterial lipid deposition, fatty acid intestinal transit, plasma concentration of triglycerides and glucose, to improve insulin sensitivity, glucose tolerance and to reduce the plasma concentration of HbAc1 in different and independent rodent models. Correlation between the anti-CD36 activity of these inhibitors and the known pathophysiological activity of this scavenger receptor in the development of atherosclerosis and diabetes were observed at pharmacological doses. Thus, CD36 might represent an attractive therapeutic target.Alain GeloenLionel HelinBenjamine GeeraertEric MalaudPaul HolvoetGerard MargueriePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 5, p e37633 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alain Geloen Lionel Helin Benjamine Geeraert Eric Malaud Paul Holvoet Gerard Marguerie CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
description	CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane associated molecules in different cells and tissues have however questioned its potential as a therapeutic target. The present study shows that it is possible to identify low molecular weight chemicals that can block the CD36 binding and uptake functions. These inhibitors were able to reduce arterial lipid deposition, fatty acid intestinal transit, plasma concentration of triglycerides and glucose, to improve insulin sensitivity, glucose tolerance and to reduce the plasma concentration of HbAc1 in different and independent rodent models. Correlation between the anti-CD36 activity of these inhibitors and the known pathophysiological activity of this scavenger receptor in the development of atherosclerosis and diabetes were observed at pharmacological doses. Thus, CD36 might represent an attractive therapeutic target.
format	article
author	Alain Geloen Lionel Helin Benjamine Geeraert Eric Malaud Paul Holvoet Gerard Marguerie
author_facet	Alain Geloen Lionel Helin Benjamine Geeraert Eric Malaud Paul Holvoet Gerard Marguerie
author_sort	Alain Geloen
title	CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
title_short	CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
title_full	CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
title_fullStr	CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
title_full_unstemmed	CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
title_sort	cd36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/4639332cd7ca4104a34711ed04f4f491
work_keys_str_mv	AT alaingeloen cd36inhibitorsreducepostprandialhypertriglyceridemiaandprotectagainstdiabeticdyslipidemiaandatherosclerosis AT lionelhelin cd36inhibitorsreducepostprandialhypertriglyceridemiaandprotectagainstdiabeticdyslipidemiaandatherosclerosis AT benjaminegeeraert cd36inhibitorsreducepostprandialhypertriglyceridemiaandprotectagainstdiabeticdyslipidemiaandatherosclerosis AT ericmalaud cd36inhibitorsreducepostprandialhypertriglyceridemiaandprotectagainstdiabeticdyslipidemiaandatherosclerosis AT paulholvoet cd36inhibitorsreducepostprandialhypertriglyceridemiaandprotectagainstdiabeticdyslipidemiaandatherosclerosis AT gerardmarguerie cd36inhibitorsreducepostprandialhypertriglyceridemiaandprotectagainstdiabeticdyslipidemiaandatherosclerosis
_version_	1718423659628986368

CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis.

Ejemplares similares